|
Index | - | P/E | - | EPS (ttm) | -6.67 | Insider Own | 1.90% | Shs Outstand | 0.91M | Perf Week | -9.84% |
Market Cap | 4.37M | Forward P/E | - | EPS next Y | -4.51 | Insider Trans | 0.00% | Shs Float | 0.74M | Perf Month | -54.70% |
Income | -5.00M | PEG | - | EPS next Q | -2.07 | Inst Own | 1.90% | Short Float / Ratio | 2.58% / 0.10 | Perf Quarter | -26.42% |
Sales | 0.90M | P/S | 4.86 | EPS this Y | 16.20% | Inst Trans | -72.20% | Short Interest | 0.02M | Perf Half Y | -65.80% |
Book/sh | 11.37 | P/B | 0.25 | EPS next Y | 53.10% | ROA | -36.70% | Target Price | 23.50 | Perf Year | -81.61% |
Cash/sh | 1.88 | P/C | 1.51 | EPS next 5Y | - | ROE | -65.00% | 52W Range | 2.63 - 32.00 | Perf YTD | -28.96% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | -126.30% | 52W High | -91.13% | Beta | - |
Dividend % | - | Quick Ratio | 1.20 | Sales past 5Y | 467.90% | Gross Margin | 87.90% | 52W Low | 8.14% | ATR | 0.62 |
Employees | 12 | Current Ratio | 1.30 | Sales Q/Q | 100.00% | Oper. Margin | - | RSI (14) | 30.79 | Volatility | 8.15% 9.11% |
Optionable | No | Debt/Eq | 0.18 | EPS Q/Q | 90.00% | Profit Margin | - | Rel Volume | 0.02 | Prev Close | 2.86 |
Shortable | Yes | LT Debt/Eq | 0.14 | Earnings | Feb 14 BMO | Payout | - | Avg Volume | 191.29K | Price | 2.84 |
Recom | 1.00 | SMA20 | -20.40% | SMA50 | -66.05% | SMA200 | -70.96% | Volume | 4,265 | Change | -0.70% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite